Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
September 20, 2018

Numab appoints immunotherapy pioneer Ignacio Melero as scientific advisor

Numab Therapeutics AG, a biopharmaceutical company developing…

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javier Melero Bermejo as scientific advisor. Ignacio Melero, M.D., Ph.D., is professor of immunology at the Academic Hospital of Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra. He leads a group working in translational tumor immunotherapy with emphasis on cell therapy, cytokine gene therapy, and immune-stimulatory monoclonal antibodies.
April 17, 2018

Numab presents preclinical data for its trispecific immuno-oncology drug ND021

Numab Therapeutics AG today presents preclinical efficacy data for…

Numab Therapeutics AG today presents preclinical efficacy data for its immuno-oncology lead product ND021 at the Annual Meeting of the American Association for Cancer Research (AACR). ND021 is a trispecific molecule that simultaneously targets PDL1 on cancer and a costimulatory receptor on T cells. The preclinical data presented today confirm the differentiating potential of ND021 in terms of efficacy and safety over PD-1/PDL1 blocking agents and their combination with antibodies targeting the costimulatory receptor. Please click on the link below to download the AACR poster presentation.
September 14, 2017

Intarcia and Numab Reach Key Milestone

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today…

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today announced the achievement of a key milestone in their on-going development partnership – the selection of a multi-specific antibody construct targeting autoimmune and inflammatory diseases. This delivery marks the first major milestone in the strategic relationship, established in the spring of 2015, and triggers a payment to Numab that will bring the total payments for this project to CHF 11.5 million to date.  
More News
Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept